Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Dipyridamole | The therapeutic efficacy of Paraoxon can be decreased when used in combination with Dipyridamole. |
| Ephedrine | Paraoxon may increase the neuromuscular blocking activities of Ephedrine. |
| Bambuterol | Paraoxon may increase the neuromuscular blocking activities of Bambuterol. |
| Clevidipine | Paraoxon may increase the neuromuscular blocking activities of Clevidipine. |
| Sar9, Met (O2)11-Substance P | Paraoxon may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P. |
| Mirabegron | Paraoxon may increase the neuromuscular blocking activities of Mirabegron. |
| Moxisylyte | Paraoxon may increase the neuromuscular blocking activities of Moxisylyte. |
| Propacetamol | Paraoxon may increase the neuromuscular blocking activities of Propacetamol. |
| Procaine | Paraoxon may increase the neuromuscular blocking activities of Procaine. |
| Cocaine | Paraoxon may increase the neuromuscular blocking activities of Cocaine. |
| Trimethaphan | Paraoxon may increase the neuromuscular blocking activities of Trimethaphan. |
| Doxacurium | Paraoxon may increase the neuromuscular blocking activities of Doxacurium. |
| Chloroprocaine | Paraoxon may increase the neuromuscular blocking activities of Chloroprocaine. |
| Tubocurarine | Paraoxon may increase the neuromuscular blocking activities of Tubocurarine. |
| Aclidinium | Paraoxon may increase the neuromuscular blocking activities of Aclidinium. |
| Butyrylthiocholine | Paraoxon may increase the neuromuscular blocking activities of Butyrylthiocholine. |
| Oxybuprocaine | Paraoxon may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Benzonatate | Paraoxon may increase the neuromuscular blocking activities of Benzonatate. |
| Succinylcholine | The metabolism of Succinylcholine can be decreased when combined with Paraoxon. |
| Tramadol | The therapeutic efficacy of Tramadol can be decreased when used in combination with Paraoxon. |
| Trospium | The therapeutic efficacy of Trospium can be decreased when used in combination with Paraoxon. |
| Oxyphenonium | The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Paraoxon. |
| Butabarbital | The therapeutic efficacy of Butabarbital can be decreased when used in combination with Paraoxon. |
| Butalbital | The therapeutic efficacy of Butalbital can be decreased when used in combination with Paraoxon. |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Paraoxon. |
| Ziprasidone | The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Paraoxon. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be decreased when used in combination with Paraoxon. |
| Talbutal | The therapeutic efficacy of Talbutal can be decreased when used in combination with Paraoxon. |
| Pentobarbital | The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Paraoxon. |
| Amitriptyline | The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Paraoxon. |
| Ipratropium | The therapeutic efficacy of Ipratropium can be decreased when used in combination with Paraoxon. |
| Methadone | The therapeutic efficacy of Methadone can be decreased when used in combination with Paraoxon. |
| Olanzapine | The therapeutic efficacy of Olanzapine can be decreased when used in combination with Paraoxon. |
| Metixene | The therapeutic efficacy of Metixene can be decreased when used in combination with Paraoxon. |
| Terfenadine | The therapeutic efficacy of Terfenadine can be decreased when used in combination with Paraoxon. |
| Buclizine | The therapeutic efficacy of Buclizine can be decreased when used in combination with Paraoxon. |
| Clozapine | The therapeutic efficacy of Clozapine can be decreased when used in combination with Paraoxon. |
| Doxylamine | The therapeutic efficacy of Doxylamine can be decreased when used in combination with Paraoxon. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Paraoxon. |
| Oxyphencyclimine | The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Paraoxon. |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Paraoxon. |
| Profenamine | The therapeutic efficacy of Profenamine can be decreased when used in combination with Paraoxon. |
| Secobarbital | The therapeutic efficacy of Secobarbital can be decreased when used in combination with Paraoxon. |
| Promazine | The therapeutic efficacy of Promazine can be decreased when used in combination with Paraoxon. |
| Hyoscyamine | The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Paraoxon. |
| Cyproheptadine | The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Paraoxon. |
| Imipramine | The therapeutic efficacy of Imipramine can be decreased when used in combination with Paraoxon. |
| Methscopolamine bromide | The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Paraoxon. |
| Metharbital | The therapeutic efficacy of Metharbital can be decreased when used in combination with Paraoxon. |
| Fluoxetine | The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Paraoxon. |
| Chlorpromazine | The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Paraoxon. |
| Darifenacin | The therapeutic efficacy of Darifenacin can be decreased when used in combination with Paraoxon. |
| Tridihexethyl | The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Paraoxon. |
| Triflupromazine | The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Paraoxon. |
| Dextromethorphan | The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Paraoxon. |
| Anisotropine methylbromide | The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Paraoxon. |
| Nortriptyline | The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Paraoxon. |
| Amoxapine | The therapeutic efficacy of Amoxapine can be decreased when used in combination with Paraoxon. |
| Atropine | The therapeutic efficacy of Atropine can be decreased when used in combination with Paraoxon. |
| Thiopental | The therapeutic efficacy of Thiopental can be decreased when used in combination with Paraoxon. |
| Nicardipine | The therapeutic efficacy of Nicardipine can be decreased when used in combination with Paraoxon. |
| Mecamylamine | The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Paraoxon. |
| Pirenzepine | The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Paraoxon. |
| Paroxetine | The therapeutic efficacy of Paroxetine can be decreased when used in combination with Paraoxon. |
| Homatropine methylbromide | The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Paraoxon. |
| Scopolamine | The therapeutic efficacy of Scopolamine can be decreased when used in combination with Paraoxon. |
| Isoflurane | The therapeutic efficacy of Isoflurane can be decreased when used in combination with Paraoxon. |
| Benzquinamide | The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Paraoxon. |
| Clidinium | The therapeutic efficacy of Clidinium can be decreased when used in combination with Paraoxon. |
| Propiomazine | The therapeutic efficacy of Propiomazine can be decreased when used in combination with Paraoxon. |
| Propantheline | The therapeutic efficacy of Propantheline can be decreased when used in combination with Paraoxon. |
| Primidone | The therapeutic efficacy of Primidone can be decreased when used in combination with Paraoxon. |
| Dicyclomine | The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Paraoxon. |
| Biperiden | The therapeutic efficacy of Biperiden can be decreased when used in combination with Paraoxon. |
| Brompheniramine | The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Paraoxon. |
| Methylphenobarbital | The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Paraoxon. |
| Quinidine | The therapeutic efficacy of Quinidine can be decreased when used in combination with Paraoxon. |
| Amantadine | The therapeutic efficacy of Amantadine can be decreased when used in combination with Paraoxon. |
| Maprotiline | The therapeutic efficacy of Maprotiline can be decreased when used in combination with Paraoxon. |
| Methantheline | The therapeutic efficacy of Methantheline can be decreased when used in combination with Paraoxon. |
| Hexafluronium | The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Paraoxon. |
| Cycrimine | The therapeutic efficacy of Cycrimine can be decreased when used in combination with Paraoxon. |
| Desloratadine | The therapeutic efficacy of Desloratadine can be decreased when used in combination with Paraoxon. |
| Glycopyrronium | The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Paraoxon. |
| Tolterodine | The therapeutic efficacy of Tolterodine can be decreased when used in combination with Paraoxon. |
| Oxybutynin | The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Paraoxon. |
| Promethazine | The therapeutic efficacy of Promethazine can be decreased when used in combination with Paraoxon. |
| Diphenhydramine | The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Paraoxon. |
| Pentolinium | The therapeutic efficacy of Pentolinium can be decreased when used in combination with Paraoxon. |
| Doxepin | The therapeutic efficacy of Doxepin can be decreased when used in combination with Paraoxon. |
| Flavoxate | The therapeutic efficacy of Flavoxate can be decreased when used in combination with Paraoxon. |
| Desipramine | The therapeutic efficacy of Desipramine can be decreased when used in combination with Paraoxon. |
| Orphenadrine | The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Paraoxon. |
| Phenobarbital | The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Paraoxon. |
| Escitalopram | The therapeutic efficacy of Escitalopram can be decreased when used in combination with Paraoxon. |
| Quetiapine | The therapeutic efficacy of Quetiapine can be decreased when used in combination with Paraoxon. |
| Levacetylmethadol | The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Paraoxon. |
| Diphenidol | The therapeutic efficacy of Diphenidol can be decreased when used in combination with Paraoxon. |
| Aripiprazole | The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Paraoxon. |
| Chlorprothixene | The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Paraoxon. |